Homocysteine, a biomarker of osteosarcoma

Kharb, Simmi; Kumar, Suresh; Kundu, Zile Singh

doi:10.4103/0973-1482.147697

Cited by 4 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the mechanism for carcinogenesis is not well understood, associated low folate levels may lead to impaired DNA synthesis, repair, and methylation . In a study of 30 patients with osteosarcoma before treatment and 30 age‐ and sex‐matched controls, Kharb et al demonstrated higher homocysteine and folate levels but lower vitamin B12 levels in osteosarcoma patients than controls …”

Section: Resultsmentioning

confidence: 99%

Blood‐borne biomarkers of osteosarcoma: A systematic review

Tan

Gerrand

Rankin

2018

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Osteosarcoma is the most common type of primary malignant bone tumor in children and young adults. Development of clinically useful biomarkers has the potential to improve treatments. The aim of this review was to investigate the recent literature assessing the utility of biomarkers for osteosarcoma. A detailed literature search was performed, with hand searches for related research publications. The search was limited to publications in English between January 2007 and February 2017. Of 286 studies identified, 24 met the inclusion criteria. There is a wide range of osteosarcoma biomarkers identified which act as clinical prognostic factors in patient outcome.

show abstract

Section: Resultsmentioning

confidence: 99%

Blood‐borne biomarkers of osteosarcoma: A systematic review

Tan

Gerrand

Rankin

2018

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…Several studies have shown that low plasma vitamin B12 concentrations are associated with cancer [ 32 , 33 , 34 , 36 , 37 ]. Therefore, many patients could undergo extensive cancer treatments while having low vitamin B12 status.…”

Section: Discussionmentioning

confidence: 99%

High Plasma Vitamin B12 and Cancer in Human Studies: A Scoping Review to Judge Causality and Alternative Explanations

Obeid

2022

Nutrients

View full text Add to dashboard Cite

Patients with cancer have been reported to show elevated plasma concentrations of vitamin B12, thus causing uncertainties regarding safety of vitamin B12. We conducted a systematic literature search and a scoping review of human studies published in PubMed between January 2005 and March 2022, to investigate the association between vitamin B12 (concentrations of B12 biomarkers, intake, and genetic determinants) and cancer. Except for liver cancer, the association between plasma vitamin B12 concentrations and cancer was not consistent across the studies. Vitamin B12 intake from food, or food and supplements, showed even less consistent associations with cancer. There was no evidence for temporality, coherence, or a biologically meaningful dose-response relationship between plasma vitamin B12 concentrations and cancer. Genetically determined high plasma vitamin B12 was likely to be associated with cancer. Available randomized controlled trials have used a high dose of multivitamin supplements and cancer was the unplanned outcome, thus the causality of B12 in cancer cannot be judged based on these trials. Additionally, low plasma vitamin B12 concentrations were common in patients with cancer. Therefore, there is not sufficient evidence to assume that high plasma vitamin B12, high B12 intake, or treatment with pharmacological doses of vitamin B12, is causally related to cancer. Low vitamin B12 status in patients with cancer needs to be diagnosed and treated in order to prevent the hematological and neurological sequela of the deficiency.

show abstract

“…A literature review showed evidence of the association among vitamin B12 and/or folate, homocysteine (HCY) and osteoblastic and osteoclastic activity, and suggested the use of these biomarkers to assess bone metabolism (e.g., in osteosarcoma) (37)(38)(39)). An analysis published in 1964 (40) focused on the decrease in ALP serum levels following vitamin B12 supplementation therapy in patients with pernicious anemia, based on the case of a patient suffering from both pernicious anemia and PDB.…”

Section: Discussionmentioning

confidence: 99%

Paget's disease of bone and megaloblastic anemia in a 72‑year‑old patient: A case report and systematic literature review

Oprea¹,

Bojincă

Balanescu

et al. 2022

Exp Ther Med

View full text Add to dashboard Cite

Paget's disease of bone (PDB) is characterized by abnormal osteoclastic bone resorption with disorganized bone neo-formation, primarily affecting elderly (>55 years) patients. Although the majority of patients are asymptomatic, some patients may experience bone pain due to local periosteal involvement or osteoarthritic lesions in the spine; in addition, limb deformities may lead to secondary gait problems or degenerative joint changes. Anemia has an overall prevalence of 12-17% in elderly adults (>65 years old), with macrocytic anemia being the less common type. Megaloblastic anemia is a macrocytic anemia characterized by the presence of large, immature, nucleated cells (megaloblasts) in the blood, with the most common cause being a deficiency of folate and/or vitamin B12. We herein report the rare case of a 72-year-old male patient exhibiting both these conditions, with the aim of discussing the possible association between the two and, most importantly, the clinical management of the patient in a real-life setting over a period of 10 years. The patient was diagnosed based on clinical symptoms (bone pain), radiological imaging and specific laboratory tests, and received discontinuous courses of bisphosphonates and cyanocobalamin supplementation therapy, based mainly on aggravated symptomatology. A systematic literature review was also performed and revealed not only the scarcity of reports on similar cases, but also the mechanisms that may underlie the possible association of PDB with macrocytic anemia due to vitamin B12 deficiency in elderly patients.

show abstract

Homocysteine, a biomarker of osteosarcoma

Cited by 4 publications

References 10 publications

Blood‐borne biomarkers of osteosarcoma: A systematic review

Blood‐borne biomarkers of osteosarcoma: A systematic review

High Plasma Vitamin B12 and Cancer in Human Studies: A Scoping Review to Judge Causality and Alternative Explanations

Paget's disease of bone and megaloblastic anemia in a 72‑year‑old patient: A case report and systematic literature review

Contact Info

Product

Resources

About